Retired MD Says The Only Safe Amount Of Alcohol Is Zero
During the 1970s, we physicians in training heard the lecture repeatedly: a drink or two a day protects the heart. The evidence was “solid.”
Red wine, in particular, was said to possess almost magical properties; its resveratrol and polyphenols were supposed to offset the toxicity of the ethanol it contained. France drank heavily and lived long. QED.
That story was wrong, and the people who promoted it knew it was at best incomplete. Forty years of research have since demolished the moderate-drinking hypothesis with the thoroughness it deserved.
The 2018 Global Burden of Disease study, published in The Lancet, analyzed data from 195 countries and reached a conclusion that left no room for negotiation: the safest level of alcohol consumption is zero. Not one drink per day. Not a glass of wine with dinner. Zero.
That finding did not end the debate. The industry funded counter-analyses. Compliant academics circulated op-eds. The New York Times health desk ran soothing pieces about Mediterranean diets.
The “one to two drinks” permission slip survives in popular culture the way bloodletting survived for centuries after the evidence against it accumulated: because moneyed interests needed it to survive.
What ethanol is
Ethanol (C2H5OH) is a two-carbon alcohol and a central nervous system (CNS) depressant. It crosses the blood-brain barrier within minutes of ingestion. Its primary mechanism involves potentiating gamma-aminobutyric acid (GABA) receptors, the brain’s main inhibitory system, while suppressing N-methyl-D-aspartate (NMDA) glutamate receptors, the primary excitatory pathway.
The result is the familiar loosening of inhibition, slowed reaction time, impaired judgment, and, at sufficient doses, unconsciousness and death.
The liver metabolizes ethanol primarily via alcohol dehydrogenase (ADH) to acetaldehyde, a compound the International Agency for Research on Cancer (IARC) classifies as a Group 1 human carcinogen.
Acetaldehyde is then converted by aldehyde dehydrogenase (ALDH) into acetate, which is excreted harmlessly. The problem is that acetaldehyde accumulates faster than ALDH clears it, above all in people with genetic variants of ALDH2, roughly half of East Asian populations, who experience flushing, nausea, and tachycardia after even small amounts of alcohol.
That reaction is not an allergy. It is the unmasked toxicity that ethanol metabolism produces in everyone, made visible because the clearance step is broken.
Ethanol’s half-life in blood is approximately four to five hours in a non-tolerant adult who has consumed one standard drink, but that figure is misleading. The liver processes roughly one standard drink per hour; binge drinking, defined by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) as 4 drinks in 2 hours for women and 5 for men, overwhelms this capacity entirely.
Blood alcohol concentration (BAC) climbs faster than the body metabolizes it, explaining why impairment persists hours after the last drink.
Chronic heavy drinkers develop tolerance through receptor downregulation, meaning the CNS compensates for persistent GABA enhancement by reducing receptor sensitivity.
Withdrawal from alcohol then becomes a medical emergency: without the drug’s artificial GABA stimulation, the excitatory system runs unchecked, producing seizures, delirium tremens (DTs), and death at rates that far exceed opioid withdrawal. Alcohol withdrawal kills. Heroin withdrawal does not, as a rule.
The numbers the industry prefers not to discuss
Alcohol kills approximately 178,000 Americans each year, according to the Centers for Disease Control and Prevention (CDC). That figure encompasses alcohol-associated liver disease, cardiovascular events, cancers, motor vehicle crashes, falls, homicides, and suicides.
It dwarfs the annual death toll from all illicit drug overdoses combined (about 107,000 in 2023, itself a record driven by fentanyl) and exceeds annual deaths from diabetes.
28.9 million Americans met the diagnostic criteria for AUD in 2023, per NIAAA data. That is roughly 1 in 9 adults. Among adults aged 18 to 25, the rate reaches 1 in 5. AUD is not a behavioral failing.
It is a neurological disorder driven by the same receptor downregulation and dopaminergic sensitization that characterizes addiction to other CNS drugs. The brain of a person with AUD differs measurably from a non-dependent brain in imaging, in receptor density, and in the expression of genes governing stress response.
Fewer than 10 percent of people with AUD receive any treatment in a given year. Compare this to treatment rates for comparable conditions: roughly 60 percent of people with hypertension receive medication.
The disparity reflects stigma, a treatment infrastructure still dominated by 12-step ideology rather than evidence-based pharmacology, and the fact that the disorder’s primary driver, the alcohol industry, has every incentive to leave it untreated.
Economic costs are conservatively estimated at $249 billion per year in the United States alone, covering lost workplace productivity, healthcare expenditures, and criminal justice costs. The global figure exceeds $1.6 trillion annually.
For comparison, the entire global annual revenue of the alcohol industry is approximately $1.6 trillion. The industry’s externalized costs, paid by taxpayers, healthcare systems, and families, equal its entire gross revenue.
A brief history of alcohol in America
Alcohol predates recorded American history; fermentation technology arrived with the first European colonists and expanded aggressively. By the early 19th century, per-capita alcohol consumption reached levels that stagger the modern imagination: roughly seven gallons of pure ethanol per person per year, compared to 2.5 gallons today.
The temperance movement, driven largely by women experiencing domestic violence and economic ruin at the hands of drinking husbands, built for decades before achieving Prohibition in 1920 with the 18th Amendment.
Prohibition, routinely dismissed as a failure, produced a 50 percent reduction in liver cirrhosis deaths, a documented reduction in domestic violence, and measurable improvements in workplace productivity.
Its repeal in 1933 reflected the industry’s political and financial power more than any coherent public health argument. The narrative of Prohibition’s failure, starring Al Capone and speakeasies, was written by the people who profited from repeal.
Post-Prohibition, the alcohol industry rebuilt itself as a normal consumer goods business, aligning with Hollywood, sports, and eventually with health researchers. The “J-curve” hypothesis, suggesting that light to moderate drinkers had better cardiovascular outcomes than abstainers, emerged in the 1980s and spread rapidly.
Subsequent analysis found that many abstainers in the comparison groups were former heavy drinkers who had quit because of illness, a confounding factor so significant it invalidated most of the literature supporting moderate drinking’s benefits.
Studies that use genetic variants in alcohol-metabolizing enzymes to separate drinking behavior from confounders have consistently found no cardiovascular benefit from moderate alcohol consumption.
The J-curve was a statistical artifact, and the researchers who pointed this out for decades faced a wall of industry-funded opposition.
Cancer: the connection the industry buried
The IARC classifies ethanol as a Group 1 carcinogen, the highest classification, meaning causation is established beyond reasonable scientific doubt. Alcohol causes cancer at seven anatomical sites: the mouth, pharynx, larynx, esophagus, liver, colon and rectum, and the female breast.
The mechanisms are multiple: acetaldehyde damages DNA directly; ethanol disrupts folate metabolism required for DNA repair; it increases estrogen levels, driving hormone-sensitive breast tumors; and it functions as a solvent, increasing mucosal permeability to other carcinogens in tobacco smoke and diet.
The dose-response relationship for breast cancer begins at one drink per day. Women who consume one alcoholic drink daily increase their breast cancer risk by roughly seven to ten percent compared to non-drinkers.
At two to three drinks daily, that risk increase reaches 20 percent. There is no threshold below which risk disappears.
A 2023 analysis published in The Lancet Oncology estimated that alcohol causes approximately 740,000 new cancer cases per year globally. In the United States, alcohol-attributable cancers account for roughly 5.4 percent of all new cancer diagnoses, or about 100,000 cases per year.
Despite this, surveys show that fewer than half of Americans are aware that alcohol causes cancer. This ignorance is not accidental. The alcohol industry has funded research, lobbying, and public messaging designed to suppress this awareness.
When the NIAAA attempted in 2023 to update its guidelines to warn that alcohol causes cancer, industry lobbyists intervened with Congress to limit the warning’s scope. The playbook was identical to the tobacco industry’s 40-year campaign to obscure the lung cancer connection.
What it does to the brain
Alcohol is neurotoxic. This is not a contested claim. At autopsy, the brains of chronic heavy drinkers show measurable volume loss in the prefrontal cortex, the cerebellum, and the white matter tracts connecting them.
Neuroimaging studies document brain atrophy after as few as 5 years of heavy drinking, and the atrophy correlates with doses that many Americans would describe as “social drinking.”
A 2017 study in the British Medical Journal, following 550 participants over 30 years, found that even moderate drinking, defined as 14 to 21 units per week (roughly 1 to 1.5 bottles of wine), associated with a three-fold higher odds of right hippocampal atrophy compared to abstainers.
The hippocampus governs memory formation. Three drinks a day, sustained over years, shrinks the structure responsible for remembering.
Alcohol’s psychiatric consequences include depression (alcohol is a CNS depressant; chronic consumption reliably induces depressive episodes), anxiety disorders through rebound hyperexcitability between drinking episodes, and psychosis at heavy doses.
The relationship between alcohol and suicide is causal and dose-dependent: acute intoxication impairs impulse control; chronic use drives the depressive states that make suicide feel rational. Approximately 25 to 30 percent of suicides in the United States involve alcohol intoxication at the time of death.
Wernicke-Korsakoff syndrome (WKS) results from thiamine (vitamin B1) deficiency in chronic heavy drinkers. Wernicke’s encephalopathy presents acutely with confusion, ataxia, and eye movement abnormalities.
Untreated, it progresses to Korsakoff psychosis, a permanent amnestic disorder in which the patient confabulates freely, fills memory gaps with fabrications, and has no insight into the deficit. Most physicians trained after 2000 have never seen a florid case because they’re not looking.
Weight gain and metabolic damage
Alcohol is calorie-dense at seven calories per gram, placing it below fat (nine calories per gram) and well above carbohydrates or protein (four calories per gram). A standard drink adds 100 to 150 calories of zero nutritional value.
But the weight problem runs deeper than calorie arithmetic. When alcohol is present in the bloodstream, the liver treats it as a metabolic priority and halts fat oxidation entirely; dietary fat consumed alongside alcohol goes into storage rather than being burned.
Alcohol also disrupts leptin and ghrelin, the hormones that govern satiety and hunger, driving overeating during and after drinking episodes. The result is preferential deposition of visceral fat, the abdominal fat that wraps internal organs and drives insulin resistance, metabolic syndrome, and cardiovascular risk far more aggressively than subcutaneous fat does.
Heavy drinkers develop the characteristic centrally obese body composition for biological reasons, not because they eat poorly. Alcohol also degrades sleep architecture, suppressing the slow-wave and REM stages that regulate cortisol and growth hormone, and sleep disruption is itself an independent driver of weight gain and impaired glucose metabolism.
The industry’s marketing of alcohol as a calorie-free indulgence, or at worst a minor dietary consideration, obscures a metabolic mechanism that helps explain why AUD and metabolic syndrome so often travel together.
The heart: revisiting the French paradox
The French paradox, the observation that French people consumed substantial saturated fat yet had relatively low rates of coronary artery disease, was attributed in the 1990s to red wine consumption and to resveratrol.
That hypothesis launched a billion-dollar resveratrol supplement industry and a decade of headlines about wine’s heart-protective properties.
The paradox was an artifact of data collection methodology: France systematically undercoded cardiac deaths on death certificates for years. The resveratrol hypothesis collapsed when clinical trials found no benefit from resveratrol supplementation, and when researchers noted that the amounts of resveratrol in a glass of wine are pharmacologically trivial compared to the doses required to produce any measurable biological effect in animal models.
The cardiovascular effects of alcohol are mixed and dose-dependent in ways that the “a drink a day is good for your heart” narrative oversimplified. Light drinking produces a modest increase in high-density lipoprotein (HDL) cholesterol and reduces platelet aggregation, effects that sounded promising in epidemiological studies.
But alcohol also raises blood pressure, increases triglycerides, induces cardiac arrhythmias (holiday heart syndrome, characterized by atrial fibrillation after binge drinking, is a recognized clinical entity), and causes alcoholic cardiomyopathy, a dilated cardiomyopathy that is the leading non-ischemic cause of heart failure in the developed world.
Liver disease: the visible iceberg tip
Alcohol-associated liver disease (ALD) is the most common cause of liver-related death in the Western world. It progresses through predictable stages: alcoholic fatty liver (steatosis), which is reversible with abstinence; alcoholic hepatitis, which has a 28-day mortality rate of 20 to 50 percent in severe cases; and alcoholic cirrhosis, which is irreversible, has a 5-year mortality of 50 percent, and requires transplantation in its end stage.
Women develop ALD at lower doses and after shorter durations of drinking than men, reflecting differences in body water content, ADH activity, and hormonal factors affecting gastric metabolism.
A woman consuming two drinks per day over several years faces liver disease risk comparable to a man consuming three to four drinks per day.
Alcohol-associated hepatitis exploded during the COVID-19 pandemic lockdowns. Hospitalizations for alcoholic hepatitis increased 30 to 50 percent at major centers between 2020 and 2022, driven by isolation, economic stress, and the removal of social constraints on drinking.
The pandemic’s secondary damage toll included this surge, which received a fraction of the attention directed at the virus itself.
This is taken from a long document, read the rest here substack.com
Header image: Getty Images